Physician profile
Bethany Perrin
NPI 1285048835
$2,447.61
in general payments reported to CMS, 2019-2025
36 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.58 · 2021: $33.94 · 2022: $210 · 2023: $573 · 2024: $892 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.83 | 2022-2025 | |
| Novo Nordisk INC | $280.64 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $203.21 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $178.17 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $132.94 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Amgen INC. | $103.84 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $100.61 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $82.82 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $77.74 | 2025 | |
| Organon LLC | $69.16 | 2023-2025 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.24 | 2023-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $60.83 | 2024 | |
| Dexcom, INC. | $50.53 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $41.34 | 2024 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $38.39 | 2024 | Voquezna |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Perrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.